{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Algernon Pharmaceuticals Announces Plans for 2021 - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"VTdjIGntKn\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-announces-plans-for-2021\/\">Algernon Pharmaceuticals Announces Plans for 2021<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-announces-plans-for-2021\/embed\/#?secret=VTdjIGntKn\" width=\"600\" height=\"338\" title=\"&#8220;Algernon Pharmaceuticals Announces Plans for 2021&#8221; &#8212; Market Newsdesk\" data-secret=\"VTdjIGntKn\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"VANCOUVER, British Columbia, Jan. 07, 2021 (GLOBE NEWSWIRE) &#8212; Algernon Pharmaceuticals Inc.\u00a0(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the \u201cCompany\u201d or \u201cAlgernon\u201d) a clinical stage pharmaceutical development company, is pleased to provide an overview of the Company\u2019s primary plans for the upcoming calendar year. New Clinical Research Programs The Company is planning to establish a minimum of one and possibly two new clinical research programs in calendar Q1, with plans to start a Phase 1 or a Phase 2 clinical trial(s) before the end of the year, for a new disease indication(s). Potential target compounds include the drugs that have been investigated by the Company in preclinical animal models or other compounds that the Company has been considering, that have established &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjEyNCMzOTA4MzE3IzIwOTIzNjc="}